Should Naloxone Be Given Routinely with Oxycodone?
No, naloxone should NOT be given routinely with oxycodone to all patients, but should be prescribed selectively based on specific risk factors for overdose and respiratory depression.
Risk-Based Naloxone Prescribing Strategy
The most recent high-quality guideline evidence supports a targeted approach rather than universal co-prescription:
Prescribe Naloxone (as rescue medication) When:
- Opioid dose ≥50 morphine milligram equivalents (MME) daily 1, 2
- Concurrent use of benzodiazepines or gabapentinoids 1, 2
- History of prior overdose 2
- History of substance use disorder 2
- Risk of unintended access by children or cognitively impaired household members 1
- Patients recently released from prison (at risk of returning to previously tolerated high doses) 2
This naloxone is for emergency rescue use only - to reverse life-threatening respiratory depression, not for routine administration 3.
The Oxycodone/Naloxone Combination Product (Different Purpose)
There is a distinct oral prolonged-release oxycodone/naloxone combination tablet (2:1 ratio) that serves an entirely different purpose:
Purpose: Managing Opioid-Induced Constipation (OIC)
- This combination uses naloxone's peripheral antagonist effects in the gut to reduce constipation 3
- Naloxone undergoes extensive first-pass hepatic metabolism, resulting in minimal systemic bioavailability, preserving central analgesia 3, 4
- May be considered for patients with OIC, but is not routinely indicated for all patients 3
Critical Safety Caveat - Hepatic Impairment:
Do NOT use oxycodone/naloxone combination in patients with:
- Cirrhosis (even if silent/unrecognized)
- Porto-systemic shunting
- Non-cirrhotic portal hypertension
- Hepatic metastases disrupting internal vasculature 5, 6, 7
Why this matters: Porto-systemic shunting bypasses first-pass metabolism, dramatically increasing systemic naloxone bioavailability. This can precipitate severe opioid withdrawal syndrome or compromise analgesia, even with normal liver function tests 5, 6, 7. Multiple case reports document opioid toxicity when converting from oxycodone/naloxone to oxycodone alone in patients with unrecognized hepatic shunting 5.
Algorithm for Decision-Making
Step 1: Assess overdose risk factors (dose ≥50 MME, benzodiazepine use, substance use history, household risks)
- YES → Prescribe rescue naloxone (intranasal or intramuscular) with caregiver education 1, 2
- NO → Rescue naloxone not routinely indicated
Step 2: Assess for opioid-induced constipation despite laxatives
- YES → Consider oxycodone/naloxone combination only after screening for hepatic impairment/shunting 3
- NO → Use standard oxycodone formulation
Step 3: Before prescribing oxycodone/naloxone combination, evaluate for:
- Clinical signs of liver disease (ascites, varices, splenomegaly)
- Imaging evidence of cirrhosis or hepatic metastases
- Remember: Normal liver function tests do NOT exclude porto-systemic shunting 6, 7
Key Clinical Pitfalls to Avoid
- Don't confuse rescue naloxone with the combination product - they serve completely different purposes
- Don't rely on liver function tests alone when considering oxycodone/naloxone - porto-systemic shunting can exist with normal labs 6
- Don't prescribe rescue naloxone without education - caregivers must understand proper indications, administration technique, and that naloxone's duration is shorter than most opioids, requiring continued monitoring 1, 8
- Don't use rescue naloxone inconsistently with goals of care - at end-of-life with comfort measures only, slowed respiration is expected and naloxone may be inappropriate 8
The evidence strongly supports selective, risk-stratified naloxone prescribing rather than routine universal co-prescription with oxycodone 1, 2.